Association of the interleukin 1 receptor antagonist gene with ulcerative colitis in Northern European Caucasians


Abstract
Background and aims—An association between the allele 2 of the interleukin 1 receptor antagonist gene variable number tandem repeats polymorphism in intron 2 and ulcerative colitis was first reported in 1994. Subsequent studies in Caucasian Northern European patients have not confirmed this, although trends towards an association were observed. The lack of statistical significance could reflect inadequate power. In this study the association was reassessed in a large independent set of well characterised Caucasian patients and a meta-analysis of reported patient series was performed.

Patients and methods—A total of 320 patients with endoscopically and histologically confirmed ulcerative colitis (124 pancolitis, 196 left sided and distal disease) and 827 ethnically matched controls were genotyped at polymorphic sites in the interleukin 1 receptor antagonist gene. Carriage rates were compared using χ² statistics. A meta-analysis of this and seven previous studies in North European Caucasian patients was performed using the Mantel-Haenszel χ² test.

Results—Patients had a significantly increased carriage rate of allele 2 compared with controls (52% v 45%; odds ratio 1.3 (95% confidence interval (CI) 1.01–1.7); p=0.04). The allele 2 carriage rate was highest in extensive colitis (carriage rate 56%; odds ratio 1.5 (95% CI 1.1–2.3); p=0.02) and in individuals who had undergone colectomy (carriage rate 55%; odds ratio 1.5 (95% CI 0.95–2.4); p=0.08). Meta-analysis of all eight studies showed a significant association between carriage of allele 2 and ulcerative colitis (odds ratio 1.23 (95% CI 1.04–1.45); p=0.01).

Conclusions—The association of the interleukin 1 receptor antagonist gene polymorphism with ulcerative colitis is confirmed. The association is minor and confers only a small risk to an individual but will contribute a high attributable risk in a population due to the high allele frequency. Accurate phenotypic characterisation defines more homogeneous subsets of patients, such as those with extensive disease, in whom the association is greater.

Keywords: ulcerative colitis; cytokine gene polymorphisms; interleukin 1 receptor antagonist; interleukin 1; inflammatory bowel disease; genetics

The causes of the common forms of idiopathic inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn’s disease (CD), remain unknown. The higher concordance rates in monozygotic compared with dizygotic twins (26% v 2%), familial clustering of disease, and ethnic variability of disease incidence suggests that genetic factors play a role. Segregation analysis indicates that a simple mendelian model of inheritance is not applicable and both the epidemiological data and clinical variability in disease suggest that IBD is a heterogeneous group of related polygenic disorders with undetermined environmental factors contributing to pathogenesis and disease phenotype. This hypothesis has been further supported by the recent genome wide linkage studies in IBD which have identified multiple candidate loci with each accounting for only a small proportion of the overall genetic risk.

Cytokines have been implicated in the pathogenesis of many chronic inflammatory diseases where genetic factors have been shown to have a role in determining disease susceptibility and severity. Furthermore, cytokines have a substantial regulatory and effector role in the mucosal immune and inflammatory response in IBD. The interleukin 1 cytokine family has been an area of considerable interest. Interleukin 1 (IL-1) alpha and beta are major proinflammatory cytokines involved early in the inflammatory cascade. The interleukin 1 receptor antagonist (IL-1ra) is the natural inhibitor of these IL-1 agonists and acts by competitively binding to IL-1 receptors without eliciting signal transduction. All three proteins are coded by genes in the IL-1 gene cluster on the long arm of chromosome 2.

Enhanced production of IL-1 has been shown in the gut tissue of animal models of intestinal inflammation, and in the colonic mucosa and by cell preparations isolated from the intestine of patients with IBD. Tissue levels correlate with disease activity but the IL-1ra/IL-1 ratio shows the closest correlation with inflammation. Furthermore, rabbit immune complex colitis is attenuated by administration of IL-1ra and reduction of IL-1ra levels by either gene knockout in mice.

Abbreviations used in this paper: IL-1ra, interleukin 1 receptor antagonist; IL-1, interleukin 1; IL-1RN, interleukin 1 receptor antagonist gene; VNTR, variable number of tandem repeats; PCR, polymerase chain reaction; SNP, single nucleotide polymorphism; IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn’s disease; OR, odds ratio.
or by antibody neutralisation in rabbits increases the susceptibility to the induction of experimental colitis. An imbalance in the biologically important IL-1ra/IL-1 ratio may therefore contribute to the chronic inflammatory response in UC. Such biological observations suggest that the IL-1 gene locus is an appropriate candidate region for studying the genetic susceptibility to UC.

A variable number of tandem repeats (VNTR) polymorphism exists within intron 2 of the IL-1ra gene (IL-1RN). Five alleles have been described but alleles 1 and 2 account for more than 95%. Subsequently, a number of single nucleotide polymorphisms (SNPs) have been described in the IL-1RN. Two such SNPs are a T to C base pair change at position +2018 in exon 2 (creating a MspI restriction site) and a C to T base pair change at position +2073 in intron 2 (disrupting a McoI restriction site). The rarer alleles of these 2 biallelic polymorphisms are completely associated with allele 2 of the intronic VNTR polymorphism.

An association between carriage of allele 2 of the intronic polymorphism and UC was first reported in 1994. This was strongest in patients with total colitis. Subsequent investigations in Jewish and Hispanic populations have confirmed this association but reports from studies on North European Caucasian populations have been conflicting. Of the five subsequent studies, none provided statistically significant evidence to confirm the genetic association although there was a trend towards an association in three. A single study showed a statistically significant negative association between the allele and the disease. A seventh study using the McoI SNP in intron 2 as a marker for the VNTR polymorphism also showed a non-significant trend towards association. However, all of these series lacked the power to exclude a false negative result. Furthermore, the diagnostic criteria used for patient selection were not uniformly clear which may have allowed inclusion of patients without UC such as those with indeterminate or Crohn’s colitis.

Therefore, the aim of our study was to reassess the putative association between allele 2 of the intronic IL-1RN polymorphism and UC. Two approaches were used. Firstly, a large independent series of clinically well characterised, unrelated, white British Caucasian patients with UC were genotyped and their carriage rate of allele 2 compared with that of a large group of ethnically matched controls. Secondly, the results of this study and those of the seven previous published studies were combined in a meta-analysis.

**Methods**

**Patients and Controls**

A total of 320 patients with UC were studied. Diagnosis and extent of disease were confirmed either by colonoscopy within the previous four years with histological examination of a colonic series of biopsies or by histological assessment of the colectomy specimen. Patients were included only if histological assessment was suggestive, highly suggestive, or diagnostic of UC according to the guidelines of the British Society of Gastroenterology. Individuals with the appearance of indeterminate chronic inflammatory bowel disease were excluded. Macroscopic and microscopic confirmation of contiguous inflammation extending for a variable distance from the rectum were necessary for inclusion. Patients with rectal sparing or focal inflammation were excluded. Where microscopic and macroscopic disease extent differed, the histological limit of inflammation was used to define disease extent. This was classified as either extensive or non-extensive depending on whether or not the inflammation extended beyond the splenic flexure. These patients represent approximately 30% of patients with UC attending our inflammatory bowel disease clinic.

The study was approved by the South Sheffield Research Ethics Committee in 1994. All patients participated in the study after giving informed written consent.

A total of 827 control individuals were anonymous blood donors in the North Trent region and all were Caucasian Northern European individuals. All samples were collected in 1997 and were independent of the control population used in the study by Mansfield and colleagues. This control DNA was collected with full ethics approval in 1997 although individuals were anonymous and did not give consent.

**Genotyping**

Blood was obtained into ethylenediaminetetraacetic acid tubes (2×10 ml) and stored frozen until extracted. DNA was extracted by a modification of the salting out technique and was stored at 4°C.

The VNTR polymorphism was genotyped as described previously. Briefly, DNA was amplified using primers flanking the 86 base pair tandem repeat polymorphic region within intron 2 of IL-1RN (sense, 5’-CTC.AGC.AAC.ACT.CCT.AT -3’ and anti-sense, 5’-TCC.TGG.TCT.GCA.GGT.TA-3’).

**Table 1** Demographic characteristics of patients with ulcerative colitis (UC)

<table>
<thead>
<tr>
<th>Total No</th>
<th>320</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (M/F)</td>
<td>160/160</td>
</tr>
<tr>
<td>Age at diagnosis (y)</td>
<td>Range 4–80</td>
</tr>
<tr>
<td>Median</td>
<td>32</td>
</tr>
<tr>
<td>Mean</td>
<td>34.5</td>
</tr>
<tr>
<td>Extent of UC (%)</td>
<td>Extensive 124 (39)</td>
</tr>
<tr>
<td>Non-extensive</td>
<td>196 (61)</td>
</tr>
<tr>
<td>Surgery (%)</td>
<td>80 (25)</td>
</tr>
<tr>
<td>Family history of IBD (%)</td>
<td>49 (15)</td>
</tr>
<tr>
<td>Family history of UC (%)</td>
<td>40 (12.5)</td>
</tr>
</tbody>
</table>

**Table 2** Demographic characteristics of patients with ulcerative colitis (UC)

**Table 3** Demographic characteristics of patients with ulcerative colitis (UC)
Polymerase chain reaction (PCR) was performed with one cycle of one minute at 96°C, 35 cycles of one minute at 94°C, one minute at 60°C, and one minute at 70°C, followed by five minutes at 70°C. PCR products were electrophoresed on a 2% agarose gel and visualised under ultraviolet light after staining with ethidium bromide.

The +2018 exon 2 SNP was genotyped as described previously.\textsuperscript{2} Briefly, a 154 base pair fragment encompassing the polymorphic site of the template DNA was amplified using a forward primer 5'-CTA.TCT.GAG.GAA.CAA.CCA.ACT.AGT.AGC-3' adjoining the polymorphic site and a reverse primer 5'-TAG.GAC.AAT.T.GCA.CCT.AGG.GTT.TGT-3'. The forward primer contains a single base mismatch two bases from the 3' end to engineer an AluI restriction site in allele 1 (AG/CTGG). Allele 2 itself completes a restriction site for MspI (AG/C GG). PCR was performed with one cycle of one minute at 96°C, 35 cycles of one minute at 94°C, one minute at 57°C, and two minutes at 70°C, followed by five minutes at 70°C. Each PCR mixture was then divided into two aliquots and separately digested with AluI or MspI. PCR products were size fractionated by 9% polyacrylamide gel electrophoresis and visualised under ultraviolet light after staining with ethidium bromide. The two enzymes cut the two alleles differently. AluI cuts the 154 base pair fragment to produce 126 and 28 base pair fragments in allele 1 while it does not digest allele 2 (154 base pairs). MspI digestion produces 125 and 29 base pair fragments in allele 2 but does not digest allele 1 (154 base pairs). Hence the two reactions (separated side by side on a gel) will give inverted patterns of digestion for homozygous individuals, and identical patterns in heterozygotes (fig 1).

Initially 269 patients and controls were genotyped for both of the above polymorphisms to confirm in a large group of individuals that allele 2 of the VNTR polymorphism and allele 2 of the exon 2 polymorphism are in 100% linkage disequilibrium. The results of this initial study are shown in table 2 and confirm that these two alleles are completely associated. Therefore, for this study we genotyped all patients and controls for the IL-1RN (+2018) polymorphism as a marker of VNTR polymorphism.

META-ANALYSIS

A Medline search of the literature and review of gastroenterology conference abstracts since 1994 identified seven studies of IL-1RN polymorphisms in UC in white Northern European Caucasian populations.\textsuperscript{21–36} Only studies which examined UC patients as a whole were included. Those series which involved any degree of selection of patients, such as those that considered only surgical patients, were excluded to ensure that the analysis reflected, as far as possible, overall disease susceptibility.

For the purposes of the meta-analysis the VNTR polymorphism is considered as collapsed into a biallelic system consisting of the disease associated allele 2 and all other alleles. This enables the results of this study and the single study using the MwoI intron 2 polymorphism to be appropriately combined with those studies in which the VNTR polymorphism itself was genotyped.

STATISTICAL METHODS

Carriage rates of allele 2 were compared between cases and controls from a 2×2 contingency table using the \( \chi^2 \) test for independence. Odds ratios were also calculated for the disease for carriage of allele 2. Observed allele frequencies have been quoted in table 3 for illustrative purposes but all analyses were performed based on genotypes rather than allele frequencies since the testing of alleles is invalid if population stratification exists. The meta-analysis was performed using the Mantel-Haenszel \( \chi^2 \) test\textsuperscript{37} with validity evaluated by the method of Mantel and Fleiss.\textsuperscript{38} Woolf’s method was used for calculating the combined odds ratio (OR) with 95% confidence intervals (CI) and to perform a statistical test of heterogeneity.\textsuperscript{39}
Extensive ulcerative colitis is defined as disease where inflammation extends beyond the splenic flexure while non-extensive disease refers to disease where the inflammation is limited to the left colon and includes left sided colitis, proctosigmoiditis, and proctitis.

To compare the current study with those performed previously by others, the power to detect an OR of 2.0 was calculated for each study (table 4). These power calculations assumed Hardy-Weinberg equilibrium, and used the control frequency for allele 2 specific for each study. Assuming an OR of 2.0, the alternative hypothesis disease allele frequency can be calculated, and hence power can be calculated using the normal approximation for testing proportions.

**Results**

**IL-1RN GENOTYPES**

Table 3 shows the IL-1RN genotypes, IL-1RN*2 carriage rate, and allele frequency for the controls, UC patients, and patient subgroups defined by extent of inflammation and surgery. These results give an allele 2 carriage rate of 52% in UC patients and 45% in healthy controls showing a significant association between carriage of allele 2 and UC (OR 1.3 (95% CI 1.01–1.7); p=0.04; \( \chi^2=4.16; 1 \text{ df} \)).

The association with allele 2 was most pronounced in patients with extensive disease, with a carriage rate of 56% (OR 1.5 (95% CI 1.1–2.3); p=0.02) compared with 52% in all UC patients and 50% in patients with left sided colitis (OR 1.2 (95% CI 0.9–1.6); p=0.3).

When patients who have required a colectomy were analysed separately there was also a trend towards association with carriage of allele 2 (55% vs 45% in controls; OR 1.3 (95% CI 0.95–2.4); p=0.08).

**META-ANALYSIS**

Details of studies, including genotypes of the patients and controls, are given in table 4. OR values for all identified studies of the IL-1RN polymorphism are given in table 4. OR values for all identified studies of the IL-1RN polymorphism in UC are shown in fig 2. Analysis of these results using the Mantel-Haenszel \( \chi^2 \) method showed an overall association between allele 2 carriage and UC (p=0.01; \( \chi^2=6.0; 1 \text{ df} \)). This result was valid according to the Mantel and Fleiss method. Woolf’s method calculated an odds ratio of 1.23 (95% CI 1.04–1.45). However, the test for heterogeneity across studies was significant (\( \chi^2=18.1; 7 \text{ df}; p=0.01 \)).

**Discussion**

This is the largest study to date assessing IL-1RN allelic carriage rates in UC. The results of the association study confirm that carriage of allele 2 is significantly associated with the disease. Although the IL-1RN association can only explain a small proportion of the overall genetic susceptibility to UC, this is in accordance with the currently accepted concept that the condition is a polygenic disorder with a potentially large number of genetic variants each contributing individually only a small genetic risk. In complex traits, although a genetic locus may confer only a small risk to the individual (compared with a monogenic disease) it may, however, have a high attributable risk in the population because of a high gene frequency. Attributable risk is the proportion of people affected with a disease due to a certain gene or genes. This may apply to the IL-1RN polymorphism. Detection of minor genes is much more difficult than identification of major genes for which the risk may be especially large.

---

**Table 3 Interleukin 1 receptor antagonist gene (IL-1RN) genotypes in controls, patients with ulcerative colitis, and in subgroups of patients with ulcerative colitis according to disease phenotype**

<table>
<thead>
<tr>
<th>IL-1RN genotype</th>
<th>Controls</th>
<th>UC</th>
<th>Colitis requiring colectomy</th>
<th>Non-extensive colitis</th>
<th>Extensive colitis</th>
<th>Ulcerative colitis</th>
<th>Controls</th>
<th>UC</th>
<th>Colitis requiring colectomy</th>
<th>Non-extensive colitis</th>
<th>Extensive colitis</th>
<th>Ulcerative colitis</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>n</em></td>
<td>1,1</td>
<td>1,2</td>
<td>2,2</td>
<td><em>n</em></td>
<td><em>n</em></td>
<td><em>n</em></td>
<td><em>n</em></td>
<td></td>
<td><em>n</em></td>
<td><em>n</em></td>
<td><em>n</em></td>
<td><em>n</em></td>
</tr>
<tr>
<td>IL-1RN*2 carriage (%)</td>
<td>44.9</td>
<td>51.6</td>
<td>55.0</td>
<td>44.9</td>
<td>51.6</td>
<td>55.0</td>
<td>44.9</td>
<td>51.6</td>
<td>55.0</td>
<td>44.9</td>
<td>51.6</td>
<td>55.0</td>
</tr>
<tr>
<td>IL-1RN*2 frequency (%)</td>
<td>25.7</td>
<td>29.8</td>
<td>32.2</td>
<td>25.7</td>
<td>29.8</td>
<td>32.2</td>
<td>25.7</td>
<td>29.8</td>
<td>32.2</td>
<td>25.7</td>
<td>29.8</td>
<td>32.2</td>
</tr>
</tbody>
</table>

---

**Table 4 Interleukin 1 receptor antagonist gene (IL-1RN) genotypes of patients with ulcerative colitis (UC) and controls, odds ratios (OR), and power of association studies in Northern European Caucasian populations**

<table>
<thead>
<tr>
<th>Study (reference)</th>
<th>Mansfield23</th>
<th>Louis24</th>
<th>Bioque27</th>
<th>Hacker28</th>
<th>Heresbach29</th>
<th>Andus30</th>
<th>Stokkers31</th>
<th>Present study</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>IL-1RN genotype</strong></td>
<td><strong>UC</strong></td>
<td><strong>HC</strong></td>
<td><strong>UC</strong></td>
<td><strong>HC</strong></td>
<td><strong>UC</strong></td>
<td><strong>HC</strong></td>
<td><strong>UC</strong></td>
<td><strong>HC</strong></td>
</tr>
<tr>
<td><strong>OR (95%CI)</strong></td>
<td>2.03 (1.30–3.18)</td>
<td>1.38 (0.78–2.45)</td>
<td>1.35 (0.73–2.49)</td>
<td>0.66 (0.37–1.20)</td>
<td>0.54 (0.30–0.96)</td>
<td>1.70 (0.78–3.71)</td>
<td>1.10 (0.62–1.97)</td>
<td>1.31 (1.01–1.69)</td>
</tr>
<tr>
<td><strong>n</strong></td>
<td>113</td>
<td>261</td>
<td>65</td>
<td>41</td>
<td>25</td>
<td>35</td>
<td>13</td>
<td>55</td>
</tr>
<tr>
<td><strong>OR (95%CI)</strong></td>
<td>1.52 (95% CI 1.04–1.45)</td>
<td>1.20 (95% CI 1.01–1.45)</td>
<td>1.20 (95% CI 1.01–1.45)</td>
<td>1.20 (95% CI 1.01–1.45)</td>
<td>1.20 (95% CI 1.01–1.45)</td>
<td>1.20 (95% CI 1.01–1.45)</td>
<td>1.20 (95% CI 1.01–1.45)</td>
<td>1.20 (95% CI 1.01–1.45)</td>
</tr>
<tr>
<td><strong>n</strong></td>
<td>46</td>
<td>55</td>
<td>21</td>
<td>20</td>
<td>19</td>
<td>25</td>
<td>19</td>
<td>22</td>
</tr>
<tr>
<td><strong>OR (95%CI)</strong></td>
<td>17</td>
<td>17</td>
<td>17</td>
<td>17</td>
<td>17</td>
<td>17</td>
<td>17</td>
<td>17</td>
</tr>
<tr>
<td><strong>Power</strong>*</td>
<td>0.58</td>
<td>0.57</td>
<td>0.57</td>
<td>0.34</td>
<td>0.47</td>
<td>0.33</td>
<td>0.33</td>
<td>0.94</td>
</tr>
</tbody>
</table>

*Power to detect an OR of 2.0 (see statistical methods).

HC, healthy controls.
Interleukin 1 receptor antagonist gene and ulcerative colitis

465

previous studies used such rigorous inclusion
with indeterminate colitis. It is unclear if the
patients where this was uncertain, such as those
confirm the disease diagnosis and excluded
with histology of a colonic series of biopsies to
study uniformly used colonoscopic assessment
2.22
completely associated with the VNTR allele
ously demonstrated that the rarer allele is also
polymorphism but the same group had previ-
this and the previous She
now be pursued for further confirmation of our
findings.

The discrepancy between the results of both
this and the previous Sheffield study;23 and
those of other white Northern European Cau-
casian series needs explanation. It is unlikely
that methodological differences can explain the
inconsistencies between studies. Six of the
seven previous investigators23 26–30 used the
same primers and protocols. Although in this
study we have used the exon 2 IL-1RN
(+2018) polymorphism as a marker for the
VNTR polymorphism, we have demonstrated
by parallel genotyping of over 269 individuals
that the rarer allele 2(C) of this single
nucleotide polymorphism is completely associ-
ated with the VNTR allele 2. A single study
from Holland31 used the intron 2 (+2073)
polymorphism but the same group had previ-
ously demonstrated that the rarer allele is also
completely associated with the VNTR allele
2.22

Ethnic differences are also unlikely to
explain the discrepancies in the results of these
studies as they were all performed in white
Northern European Caucasians. However,
there was variability in allele 2 carriage rates in
the control populations, varying from 35% to
52%, which may explain some of the inconsist-
encies between studies. This is likely to reflect
the limited number of controls used in several
of the series. In association studies it is
optimum to have twice as many controls as
cases and this criterion was fulfilled in our
present investigation which had the largest
number of controls.

Variation in diagnostic criteria and methods
of patient assessment may be relevant. In view
of similarities between UC and CD and in the
absence of sensitive and specific serological
tests for distinguishing these related condi-
tions, most authorities accept that colonoscopy
with colonic biopsies is the most accurate and
reliable method of confirming disease diagno-
sis.42 Even with such investigations it can still
be impossible to distinguish between UC and CD
in approximately 20% of cases. This present
study uniformly used colonoscopic assessment
with histology of a colonic series of biopsies to
confirm the disease diagnosis and excluded
patients where this was uncertain, such as those
with indeterminate colitis. It is unclear if the
previous studies used such rigorous inclusion
criteria.

Different sets of genes may result in similar
disease expression in different individuals and
UC may in fact represent a number of distinct
but closely related disorders that share some
but not all genetic factors. This may explain the
variable disease behaviour seen in clinical practice. The concept of genetic and pheno-
typic heterogeneity within UC, and indeed
IBD as a whole, is an area of considerable
interest.43 Such genetic heterogeneity has been
suggested as an explanation for the differences
in the results of these studies.29 Perhaps allele 2
of the IL-1RN is associated exclusively with a
particular phenotype of UC. Disease extent,
need for surgery, and familial disease are the
most widely discussed phenotypes in IBD. Com-
parison of the studies with respect to
tent of disease show similar proportions of
individuals with distal, left sided, and extensive
disease, and these proportions accord well with
previous published series of disease extent in
UC.44 Due to the absence of data it is not pos-
sible to compare the studies with respect to
surgery or familial disease. It is difficult
however to explain why the proportions of the
putative different phenotypes, even if as yet
undefined, should be significantly different
between two centres in the same country. Fur-
thermore, this current study represents results
from over 30% of patients attending a single
centre with UC which argues against case
selection.

The most plausible explanation for the
differences in the results of these similar stud-
ies may lie in the sample sizes and hence lack of
power. The previous seven studies had at least
54 and at most 113 patients, which gives a
power to detect an OR of 2.0 of 33% and 58%,
respectively, whereas the current study of 320
patients has a power of 94% (see table 4). We
suggest that the previous non-confirmatory
studies may simply represent false negatives
due to lack of power to detect a small increase
in allele frequency in patients. Indeed, three of
these six studies showed a non-significant trend
towards association with ORs which were
higher than our current study.26 27 30

To verify this hypothesis a meta-analysis of all
studies in Northern European Caucasian
populations was performed and this confirmed
an overall association. This also provided
evidence of heterogeneity between the studies
suggesting that the association may not be
present in all disease groups even within such a
well defined population and that therefore
there may exist more than one disease pathway.
However, it appears that one study29 is respon-
sible for most of the heterogeneity observed.
Indeed, close analysis of the UC patients
included in this study show that none had been
-treated with azathioprine, suggesting selection
of cases, which may explain the heterogeneity
observed. For interest, we then performed the
meta-analysis omitting this study29 in an
attempt to increase homogeneity. This gave an
OR of 1.3 (95% CI 1.1–1.6; p=0.001; \( \chi^2 = 10.2, 1 \text{ df} \)). Woolf’s test for heterogeneity is then no
longer significant (\( \chi^2 = 9.6; 6 \text{ df}; p=0.14 \))
suggesting that the discrepancies are not that
great. Although all meta-analyses suffer from
publication bias, we have included both published studies and those presented in abstract form. In this meta-analysis, we found that the polymorphism is a marker of disease extent. This concurs with the original subgroup analysis in the Sheffied study and that of a Dutch study, and also recent data from Oxford. Classifying UC by extent of disease can however be difficult as this has been variously defined by radiological, endoscopic, and histological criteria in different studies. Furthermore, it has been suggested that the extent of colonic involvement in UC is dynamic and not static and may extend or regress during the course of the disease. The requirement for colectomy in UC is a further phenotypic classification that has clinical relevance in terms of disease severity. In this study there was an increased carriage rate of the allele 2 in the subgroup of patients undergoing colectomy although the small number of patients makes it difficult to draw definitive conclusions. Previous data have been contradictory with subgroup analysis of the French study demonstrating an association with carriage of the allele 2 while data from Oxford failed to confirm this.

Recent observations have suggested that allele 2 of the IL-1RN gene is associated with reduced levels of IL-1ra in the colonic mucosa of patients with IBD and unpublished data. This may prevent adequate control of mucosal inflammation and provides a biologically plausible mechanism for the genetic association between the allele and the disease. However, the VNTR polymorphism is a non-coding region of the gene in intron 2 and the exon 2 polymorphism is a conservative base pair change which does not alter the protein amino acid sequence. It is difficult to envisage how either polymorphism has a direct functional effect in terms of IL-1ra production and indeed unpublished gene reporter studies showed that the VNTR itself had no effect on gene transcription (personal communication). It is therefore likely that both polymorphisms are in linkage disequilibrium with a functional polymorphism, as yet undefined. This genetic functional change is perhaps most likely to be either in the gene promoter region or in the 3' untranslated region, affecting gene transcription or post-transcriptional events, respectively. Alternatively, although less likely, is the possibility that the demonstrated association is due to linkage disequilibrium with a genetic variant in another gene (perhaps yet to be characterised) within the gene cluster, due to the presence of linkage disequilibrium. Indeed, four novel genes have recently been identified within the IL-1 gene cluster.

In summary, this is the largest association study to date in well defined patients with UC, assessing the putative genetic association with allele 2 of the IL-1RN. The association with disease was confirmed and this conclusion is supported by a meta-analysis of the previous studies in North European Caucasians. In addition, the allele 2 may also be a determinant of disease severity in terms of extent of disease and the need for surgery.

This research was funded by the National Association of Colitis and Crohn's Disease and the Special Trustees of the Former United Central Sheffield Hospitals. Dr M J Carter is a Digestive Disorders Foundation Research Training Fellow.

Conflict of interest. F S di Giovine and G W Duff are co-holders of patents on IL-1 genes as susceptibility markers for inflammatory diseases.

Interleukin 1 receptor antagonist gene and ulcerative colitis


